Nolan T, Geffert L, Kolber B, Madura J, Surratt C. Discovery of novel-scaffold monoamine transporter ligands via in silico screening with the S1 pocket of the serotonin transporter. ACS Chem Neurosci. 2014;5:784-92 pubmed publisher

Su D, Jiang R, Liu N, Ding L, Wang D, Yu H, et al. Effects of BD1047, a ?1 receptor antagonist, on the expression of mTOR, Camk2? and GSK-3? in fluvoxamine-treated N2a cells. Exp Ther Med. 2014;7:435-438 pubmed

Agarwal J, Zhu Y, Zhang Q, Mongin A, Hough L. TRAM-34, a putatively selective blocker of intermediate-conductance, calcium-activated potassium channels, inhibits cytochrome P450 activity. PLoS ONE. 2013;8:e63028 pubmed publisher

Fishback J, Rosen A, Bhat R, McCurdy C, Matsumoto R. A 96-well filtration method for radioligand binding analysis of ? receptor ligands. J Pharm Biomed Anal. 2012;71:157-61 pubmed publisher

Wood W, Lovell P, Mello C, Perkel D. Serotonin, via HTR2 receptors, excites neurons in a cortical-like premotor nucleus necessary for song learning and production. J Neurosci. 2011;31:13808-15 pubmed publisher

O Donnell E, Saili K, Koch D, Kopparapu P, Farrer D, Bisson W, et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS ONE. 2010;5: pubmed publisher

Hirano K, Kimura R, Sugimoto Y, Yamada J, Uchida S, Kato Y, et al. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol. 2005;144:695-702 pubmed

Kobayashi T, Washiyama K, Ikeda K. Inhibition of G protein-activated inwardly rectifying K+ channels by various antidepressant drugs. Neuropsychopharmacology. 2004;29:1841-51 pubmed